The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A Phase 2 Exploratory Study of Mavrilimumab versus Anti-Tumor Necrosis Factor in Subjects with Rheumatoid Arthritis
- collapse A Phase 2, Randomized Dose-Ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis
- collapse An Open-Label Extension Study to Evaluate the Long-Term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis
- collapse A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects with Moderate-to-Severe Rheumatoid Arthritis
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers
- collapse A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease
- collapse A Phase 2 Open-Label Study to Evaluate the Long-Term Safety of Sifalimumab in Adult Subjects with Systemic Lupus Erythematosus or Myositis
- collapse A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus
- collapse A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-Like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus and Parainfluenza Virus Type 3, in Healthy 6 to <24 Month-Old Children and in 2 Month Old Infants
- collapse A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
